Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses
Vaccines based on mRNA and viral vectors are currently used in the frontline to combat the ongoing pandemic caused by the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). However, there is still an urgent need for alternative vaccine technologies inducing/boosting long-lasting and...
Main Authors: | Kirsi Tamminen, Suvi Heinimäki, Stina Gröhn, Vesna Blazevic |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/7/733 |
Similar Items
-
Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only
by: Suvi Heinimäki, et al.
Published: (2020-07-01) -
Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in <i>Nicotiana benthamiana</i>
by: Maria Malm, et al.
Published: (2019-05-01) -
Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo
by: Kirsi Tamminen, et al.
Published: (2020-01-01) -
A Nanoparticle-Based Trivalent Vaccine Targeting the Glycan Binding VP8* Domains of Rotaviruses
by: Ming Xia, et al.
Published: (2021-01-01) -
Glycan binding patterns of human rotavirus P[10] VP8* protein
by: Li-li Pang, et al.
Published: (2018-10-01)